AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31851093
Drug: 10-day dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-day dual therapy (esomeprazole 20 mg and amoxicillin 750 mg, q.i.d.)
Trial: 31851093
Drug: 14-day dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14-day dual therapy (esomeprazole 20 mg and amoxicillin 1000 mg, t.i.d.)
Trial: 19104814
Drug: Capecitabine (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (2,000 mg/(m(2) day) on days 1-14) and Irinotecan (250 mg/m(2) every 3 weeks)
Trial: 7852519
Drug: hGH replacement
RxNorm normalized name: hGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH replacement therapy (12.5 micrograms/kg BW, self-administered daily sc)
Trial: 2094113
Drug: Etofenamate 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate 10% cream
Trial: 728318
Drug: Combined preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparation of (+)-norpseudoephedrine and senna
Trial: 28225674
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg
Trial: 28225674
Drug: Lanadelumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 400 mg
Trial: 21898496
Drug: sorafenib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 800 mg/day
Trial: 21898496
Drug: sorafenib half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib half dose
Trial: 31391334
Drug: sorafenib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib therapy
Trial: 20015433
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese herbal medicine plus conventional treatment
Trial: 16467013
Drug: Physician characteristics
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician characteristics (e.g., professional orientation, location, and experience)
Trial: 16467013
Drug: Patient factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient factors (e.g., contact with drug subculture, appearance, employment status, social support, having children)
Trial: 9353692
Drug: Doxacurium administered
RxNorm normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxacurium administered by bolus injection
Trial: 9353692
Drug: Doxacurium administered
RxNorm normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxacurium administered by 10-min infusion
Trial: 9353692
Drug: Doxacurium with
RxNorm normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxacurium with Rtot model (infusion)
Trial: 6393937
Drug: Rectal metronidazole
RxNorm normalized name: metronidazole Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal metronidazole
Trial: 28554530
Drug: Electrical Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Muscle Stimulation (EMS) treatment, 3 times over a period of 1 week, 1-hour sessions each.
Trial: 28554530
Drug: Electrical Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Muscle Stimulation (EMS) treatment
Trial: 26424212
Drug: SUA quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUA quartile III (281-420 mmol/L)
Trial: 26424212
Drug: SUA quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUA quartile IV (420-1640 mmol/L)
Trial: 23865335
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation of oxaprozin enteric coated tablets (0.4 g)
Trial: 23865335
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation of oxaprozin enteric coated tablets (0.4 g)
Trial: 21547496
Drug: Vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 100 mg (n=26)
Trial: 19002650
Drug: Sertraline usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline usual formulation
Trial: 19002650
Drug: Sertraline liquid
RxNorm normalized name: sertraline Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline liquid oral concentrate (LOC) formulation
Trial: 15964100
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (20 or 40 IU)
Trial: 11461738
Drug: Propranolol (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1.6 mg/kg/day)
Trial: 8091754
Drug: Live cold-adapted
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold-adapted attenuated vaccine
Trial: 8091754
Drug: Whole-virus inactivated
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus inactivated trivalent vaccine
Trial: 8091754
Drug: All vaccines
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccines (including live and inactivated)
Trial: 8091754
Drug: Revaccinated children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccinated children with preexisting antibody
Trial: 28871961
Drug: Vaccine strains
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine strains
Trial: 29231342
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling pretreatment (once a day) at specific acupuncture points for three months before embryo transfer, along with antibiotics and oral progesterone after ovulation.
Trial: 29231342
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with antibiotics in the menstrual period and oral progesterone after ovulation.
Trial: 25925226
Drug: HOME Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOME Plus intervention (community-based program with ten monthly sessions and five motivational calls)
Trial: 18551819
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA morphine only (Morphine PCA group, n = 90)
Trial: 18551819
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA morphine only (Morphine PCA group)
Trial: 16520410
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of ginseng for 12 weeks
Trial: 12775894
Drug: Emla cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emla cream
Trial: 10551577
Drug: Ropivacaine (0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.25%, 1 ml/kg)
Trial: 10551577
Drug: Bupivacaine (0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.25%, 1 ml/kg)
Trial: 1860289
Drug: Malarial chemoprophylaxis
RxNorm normalized name: malarial plasmodium group immunoserum rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malarial chemoprophylaxis (300 mg chloroquine weekly for at least one year)
Trial: 31123090
Drug: Bedsheet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedsheet and intravenous pole
Trial: 18715524
Drug: Rivaroxaban 50
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 50 mg
Trial: 16423208
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin therapy
Trial: 16423208
Drug: Intravenous OK432
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous OK432 therapy
Trial: 16423208
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cisplatin and OK432
Trial: 15052382
Drug: Methylprednisolone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1000 mg i.v.)
Trial: 15052382
Drug: Sivelestat (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.20 mg/kg per h)
Trial: 15052382
Drug: Immunoglobulin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (5 g for 3 days)
Trial: 15052382
Drug: Sivelestat (0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.004 mg/kg per h)
Trial: 8823657
Drug: FEV1 residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEV1 residual less than -1.2 L (optimal cut-off)
Trial: 6380858
Drug: Once-daily metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily metoprolol (Betaloc tablets)
Trial: 6380858
Drug: Twice-daily metoprolol
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily metoprolol (Betaloc Durules)
Trial: 3524185
Drug: Potassium-sparing diuretic
RxNorm normalized name: Potassium-sparing diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-sparing diuretic amiloride
Trial: 29759656
Drug: Emergency medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency medicine residency training
Trial: 27929346
Drug: d-amphetamine 1
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 1 mg
Trial: 27929346
Drug: d-amphetamine 2
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 2 mg
Trial: 25045832
Drug: Probiotic-enriched foods
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-enriched foods or dietary supplement containing SYNBIO®
Trial: 20810998
Drug: Donepezil (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (maximum 10 mg per day)
Trial: 19075497
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid at 1 mg/day
Trial: 10232867
Drug: Daily averages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily averages of symptoms
Trial: 10232867
Drug: Weekly averages
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly averages of symptoms
Trial: 10232867
Drug: 2-week intervals
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week intervals during treatment
Trial: 1925430
Drug: Individually planned
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individually planned energy-restricted diet of 1000-1500 kcal per day, weekly discussions, and various leaflets on diet modification and increase of physical activity
Trial: 6660028
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (20 g X 4/day)
Trial: 6660028
Drug: Haemodialysis (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemodialysis (3 treatments of 5 hours each)
Trial: 28957643
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg tiotropium Respimat
Trial: 28957643
Drug: 18 μg
RxNorm normalized name: ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 μg HandiHaler
Trial: 22472154
Drug: morphine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (0.05 mg/kg) IV during gallbladder extraction and (0.15 mg/kg) for 40 min postoperatively
Trial: 22472154
Drug: ketorolac (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac (0.2 mg/kg) IV during gallbladder extraction and (0.7 mg/kg) for 40 min postoperatively
Trial: 20353029
Drug: Modified Huanglian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Huanglian Wendan Decoction (HWD) 200 mL, twice a day
Trial: 20353029
Drug: Aniracetam 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aniracetam 0.2 g (0.1 g for patients over 70), three times a day
Trial: 16107896
Drug: AML-92/94 protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AML-92/94 protocol (modified BFM-93) without maintenance therapy and prophylactic cranial irradiation
Trial: 11810342
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (8 group sessions)
Trial: 9231815
Drug: ET-1 infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 infusion (0.5 ng/kg per minute for 60 minutes, then 1.0 ng/kg per minute for 60 minutes, and finally 2.0 ng/kg per minute for 60 minutes)
Trial: 8186511
Drug: L-phenylalanine (L-Phe)
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine (L-Phe) plus UVA irradiation
Trial: 8186511
Drug: Increased L-phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased L-phenylalanine dose
Trial: 8186511
Drug: Optimal L-phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal L-phenylalanine dose
Trial: 25423323
Drug: Bilateral salpingo-oophorectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral salpingo-oophorectomy (BSO) without subsequent hormone therapy (HT)
Trial: 22722891
Drug: Almond diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond diet (56 g/day, replacing 20% of total daily calorie intake)
Trial: 7959144
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream (2%)
Trial: 27686943
Drug: Temozolomide chemotherapy
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide chemotherapy (75 mg/m2 daily, for 21 of 28 days for 12 cycles)
Trial: 19929975
Drug: AZ-ER (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ-ER (single oral 2-g dose)
Trial: 19929975
Drug: AZ-IR (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ-IR (3 days, 500 mg once daily)
Trial: 16387893
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g i.v. carnitine
Trial: 12243707
Drug: Oral ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoconazole 600 mg/day for adults and 10 mg/kg per day for children for 30 days
Trial: 12243707
Drug: Intra-lesional meglumine
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-lesional meglumine antimoniate (Glucantime) with 6-8 biweekly injections
Trial: 7900613
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use (even infrequent)
Trial: 2670331
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (50%), insulin (80 units/I), and potassium (100 meq/l) (GIK) infused at a rate of 1 ml/kg/hr for up to 48 hours
Trial: 31189511
Drug: Dulaglutide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (1.5 mg weekly subcutaneous injection)
Trial: 17950093
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous insulin infusion (3 one-hour courses per week)
Trial: 17950093
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (3-4 injections per day)
Trial: 17950093
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous insulin infusion
Trial: 16342005
Drug: Lithium serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium serum levels > 0.5 meq/l
Trial: 11928799
Drug: 5‐fluorouracil (5‐FU)‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU)‐based chemotherapy
Trial: 9456255
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement with arginine and omega-3 fatty acids
Trial: 9456255
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement without arginine and omega-3 fatty acids (Control)
Trial: 28391912
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day for 4 weeks then 20 mg/day for 16 weeks
Trial: 21719555
Drug: Darbepoetin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darbepoetin (60 μg/injection)
Trial: 17711731
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: Propofol 2 microg/ml and Rimifentanil 2 ng/ml with fluid expansion of Hetastarch 5 ml/kg
Trial: 17711731
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (Control): Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Trial: 17711731
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: Propofol 4 microg/ml and Rimifentanil 4 ng/ml with fluid expansion of Hetastarch 10 ml/kg
Trial: 7788917
Drug: Low-dose isoproterenol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isoproterenol infusion during tilt testing at 60 degrees
Trial: 7788917
Drug: Low-dose isoproterenol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isoproterenol infusion during tilt testing at 70 degrees
Trial: 7788917
Drug: Low-dose isoproterenol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isoproterenol infusion during tilt testing at 80 degrees
Trial: 7788917
Drug: Tilt testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt testing at 70 degrees with 1.5 micrograms/min isoproterenol infusion
Trial: 7788917
Drug: Tilt testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt testing at 70 degrees with 3 micrograms/min isoproterenol infusion
Trial: 7788917
Drug: Tilt testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt testing at 70 degrees with 5 micrograms/min isoproterenol infusion
Trial: 7788917
Drug: Tilt testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt testing during 3 micrograms/min isoproterenol infusion
Trial: 7788917
Drug: Tilt testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilt testing during 5 micrograms/min isoproterenol infusion
Trial: 1098155
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mebendazole twice a day for three days
Trial: 1098155
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mebendazole twice a day for four days
Trial: 28246206
Drug: gemcitabine/simtuzumab 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine/simtuzumab 700 mg
Trial: 28246206
Drug: gemcitabine/simtuzumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine/simtuzumab 200 mg
Trial: 26939315
Drug: Acupuncture (Tianshu,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (Tianshu, Zusanli, Shangjuxu, Taichong, Sanyinjiao, Yintang, Baihui), once a day, 5 treatments a week for 4 weeks.
Trial: 26939315
Drug: Lactulose oral
RxNorm normalized name: lactulose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose oral solution, 15 mL three times a day for 4 weeks.
Trial: 26939315
Drug: Lactulose oral
RxNorm normalized name: lactulose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose oral solution (same as above)
Trial: 23936893
Drug: Distressed preneedle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distressed preneedle toddlers (regardless of treatment group)
Trial: 18430242
Drug: Subgrouping using
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgrouping using a novel tool combined with targeted treatment delivered by trained physiotherapists
Trial: 12930428
Drug: Adjuvant intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravesical sequential bacillus Calmette‐Guérin (BCG) and epirubicin
Trial: 12930428
Drug: Epirubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (50 or 80 mg)